Use the hyperlinks, where available to access additional clinical trial information.
Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma
This trial is for adults with relapsed and refractory multiple myeloma who have failed 3 or more different prior lines of therapy and who have measurable disease at enrolment per IMWG criteria. In addition, participants must be refractory to the last line of therapy. Eligible participants will receive PHE885, which will be administered via intravenous injection.